Overview

The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction

Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This research is studying a drug called dupilumab to learn about its safety and its effect as a treatment for participants with dermal hypersensitivity reaction. This study will help better understand why and how dermal hypersensitivity reaction occurs and how dupilumab might help treat this condition.
Phase:
Phase 4
Details
Lead Sponsor:
University of Michigan
Collaborator:
Regeneron Pharmaceuticals